Unknown

Dataset Information

0

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.


ABSTRACT: PURPOSE:To analyze the quality of life (QOL) and performance status (PS) (secondary outcome) in patients with stage III to IV head and neck cancer (HNC) enrolled on a prospective randomized phase 3 trial comparing radiation-cisplatin without cetuximab (CIS) or with cetuximab (CET/CIS). The QOL hypothesis proposed a between-arm difference in Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN) total score of ?10% of the instrument range from baseline to 1 year. METHODS AND MATERIALS:Patients who gave consent to the QOL/PS study completed the FACT-HN, Performance Status Scale for HNC (PSS-HN), and EuroQol (EQ-5D) at baseline through to 5 years. The pretreatment QOL/PS scores were correlated with outcome and p16 status in patients with oropharyngeal cancer (OPC). RESULTS:Of 818 analyzable patients, the 1-year change from baseline score for FACT-HN total was -0.41 (CIS arm) and -5.11 (CET/CIS arm) (P=.016), representing a 3.2% between-arm change of the FACT-HN total score. The mean EQ-5D index and PSS-HN scores were not significantly different between arms. The p16-positive OPC patients had significantly higher baseline and 1-year scores for PSS-HN, FACT-HN total, physical and functional subscales, and 2-years for the EQ-5D index compared with p16-negative OPC patients. Higher pretreatment PSS-HN diet, PSS-HN eating, FACT-HN, and EQ-5D index scores were associated with better overall survival (OS) and progression-free (PFS) survival on multivariate analysis. Higher baseline FACT-HN total, functional, physical subscale, and EQ-5D index scores were associated with improved OS and PFS in p16-positive OPC patients but not in p16-negative and non-OPC patients. CONCLUSION:There was no clinically meaningful difference in QOL/PS between arms. The p16-positive OPC patients had significantly higher QOL/PS than did p16-negative patients. Pretreatment QOL/PS is a significant independent predictor of outcome in locally advanced HNC.

SUBMITTER: Truong MT 

PROVIDER: S-EPMC5303682 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.

Truong Minh Tam MT   Zhang Qiang Q   Rosenthal David I DI   List Marcie M   Axelrod Rita R   Sherman Eric E   Weber Randal R   Nguyen-Tân Phuc Felix PF   El-Naggar Adel A   Konski André A   Galvin James J   Schwartz David D   Trotti Andy A   Silverman Craig C   Singh Anurag A   Godette Karen K   Bonner James A JA   Jones Christopher U CU   Garden Adam S AS   Shenouda George G   Matthiesen Chance C   Le Quynh-Thu QT   Bruner Deborah D  

International journal of radiation oncology, biology, physics 20160812 4


<h4>Purpose</h4>To analyze the quality of life (QOL) and performance status (PS) (secondary outcome) in patients with stage III to IV head and neck cancer (HNC) enrolled on a prospective randomized phase 3 trial comparing radiation-cisplatin without cetuximab (CIS) or with cetuximab (CET/CIS). The QOL hypothesis proposed a between-arm difference in Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN) total score of ≥10% of the instrument range from baseline to 1 year.<h4>Methods and m  ...[more]

Similar Datasets

| S-EPMC5266672 | biostudies-literature
| S-EPMC4162493 | biostudies-literature
| S-EPMC10247515 | biostudies-literature
| S-EPMC6007748 | biostudies-literature
| S-EPMC4540628 | biostudies-literature
| S-EPMC9019849 | biostudies-literature
| S-EPMC8238825 | biostudies-literature
| S-EPMC8078254 | biostudies-literature
| S-EPMC8783635 | biostudies-literature
| S-EPMC6368223 | biostudies-literature